Monument Therapeutics utilizes digital biomarkers to identify patients with similar brain biology, enhancing the likelihood of effective responses to targeted treatments for cognitive impairment associated with schizophrenia and neuroinflammation. The company addresses the high failure rates of neuroscience drugs in clinical trials due to biological differences among patients by applying precision medicine principles to drug development.
Funding
$6.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug development for cognitive impairment and other neurological conditions faces high failure rates due to the biological variability among patients. This heterogeneity makes it difficult to identify which patients will respond to specific treatments, leading to inefficient clinical trials and delayed access to effective therapies.
Solution
Monument Therapeutics employs digital biomarkers to stratify patients based on their underlying brain biology, enabling a precision medicine approach to neuroscience drug development. By identifying subgroups of patients with similar biological profiles, Monument Therapeutics aims to increase the likelihood of successful clinical trials and improve treatment outcomes. Their approach involves using proprietary digital biomarkers and novel formulations of well-characterized CNS-active small molecules to accelerate the development of targeted therapies for cognitive impairment associated with schizophrenia and neuroinflammation. This strategy seeks to address the root causes of treatment failure by matching the right patients with the right drugs.
Target Audience
The primary target audience includes individuals with cognitive impairment associated with schizophrenia and neuroinflammation, as well as pharmaceutical companies seeking to improve the efficiency and success rates of their neuroscience drug development programs.
Features
- Proprietary digital biomarkers for patient stratification based on brain biology.
- Targeted treatments for cognitive impairment associated with schizophrenia.
- Targeted treatments for neuroinflammation.
- Novel formulations of well-characterized CNS-active small molecules.
- Clinical-stage pipeline with near-term commercial potential.